A phase I dose-escalation study of the polyamine analog PG-11047 in patients with advanced solid tumors.

ABSTRACT:

Purpose

Polyamines are essential for the sustained proliferation and biomass required by tumor cells. Bis-alkylated polyamine analogs are nonfunctional competitors of natural polyamines. Of these, PG-11047, a second-generation unsaturated analog of the polyamine spermine, has demonstrated anticancer activity in cell lines and animal models of multiple cancer types. This report describes the first phase I clinical trial to investigate PG-11047 in patients with advanced refractory metastatic solid tumors.

Methods

Forty-six patients were treated with 60-min intravenous infusions of PG-11047 using a 28-day dosing cycle with treatments on days 1, 8, and 15. Doses ranged from 50 to 750 mg. The treatment period consisted of at least two cycles.

Results

The maximum tolerated

SUBMITTER: Murray Stewart T 

PROVIDER: S-EPMC7337042 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature